Houston chemist lands $2M NIH grant for cancer treatment research

future of cellular health

The funds were awarded to Han Xiao, a scientist at Rice University.

A Rice University chemist has landed a $2 million grant from the National Institute of Health for his work that aims to reprogram the genetic code and explore the role certain cells play in causing diseases like cancer and neurological disorders.

The funds were awarded to Han Xiao, the Norman Hackerman-Welch Young Investigator, associate professor of chemistry, from the NIH's Maximizing Investigators’ Research Award (MIRA) program, which supports medically focused laboratories.

Xiao will use the five-year grant to develop noncanonical amino acids (ncAAs) with diverse properties to help build proteins, according to a statement from Rice. He and his team will then use the ncAAs to explore the vivo sensors for enzymes involved in posttranslational modifications (PTMs), which play a role in the development of cancers and neurological disorders. Additionally, the team will look to develop a way to detect these enzymes in living organisms in real-time rather than in a lab.

“This innovative approach could revolutionize how we understand and control cellular functions,” Xiao said in the statement.

According to Rice, these developments could have major implications for the way diseases are treated, specifically for epigenetic inhibitors that are used to treat cancer.

Xiao helped lead the charge to launch Rice's new Synthesis X Center this spring. The center, which was born out of informal meetings between Xio's lab and others from the Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center at the Baylor College of Medicine, aims to improve cancer outcomes by turning fundamental research into clinical applications.

They will build upon annual retreats, in which investigators can share unpublished findings, and also plan to host a national conference, the first slated for this fall titled "Synthetic Innovations Towards a Cure for Cancer.”

From Your Site Articles
Rice University's SynthX Center, a collaborative lab focused on cancer treatments, named its inaugural seed grant recipients. Photo via Getty Images

3 Houston cancer-focused research projects receive seed grants from new innovative initiative

funding the future

Three groundbreaking projects have just received seed grants from a new Houston-based source.

This spring, Rice University launched its Synthesis X Center with the goal of fostering the growth of cancer technologies and medications. Now, the SynthX, as it is known, and Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center have announced joint awards of grants to promising teams, all of which have principals at either Rice or Baylor.

The teams include:

  • A project from Drs. Pabel Miah of Baylor and Lei Li of Rice that involves the development and optimization of high-resolution imaging technology that’s intended for use in removing breast cancer from patients. The researchers combine ultrasound with photoacoustic technology to produce real-time imaging that allows surgeons to spot hard-to-locate tumors. This could reduce or eliminate tumor localization procedures which are invasive and costly.
  • A leukemia treatment profiting from molecular jackhammers, a type of molecule invented in the Rice University lab of Dr. James Tour. He’s joined in the project by Drs. Xin Li and Yongcheng Song, both of Baylor. Molecular jackhammers vibrate more than a trillion times per second when activated by a specific light frequency. Doing this can kill nearby cancer cells. The new treatment is intended to disrupt the activity of a transcription protein called ENL that helps fuel the growth of leukemia cells in several acute forms of the disease.
  • A project that could discover how to inspire cancer cells to kill themselves, using a cancer-associated enzyme called lysine demethylase 4A. Baylor’s Dr. Ruhee Dere and Rice’s Dr. Anna Karin-Gustavsson are studying the KDM4A with the process of apoptosis, or programmed cell death, in mind for the aberrant cells.

The seed grants are managed by Rice’s office for Educational and Research Initiatives for Collaborative Health (ENRICH). Each of the three grants is intended to last two years and includes funds of up to $80,000.

The goal is to allow research teams to collect preliminary data that can be used to apply for more substantial grants from bodies like the Cancer Prevention and Research Institute of Texas (CPRIT) or the National Institute of Health (NIH).

Three quarters of the funds will be provided in the first year. Teams that produce grant submissions with multiple principal investigators in that first year will be eligible to collect the additional quarter.

CellChorus created a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. Photo via Getty Images

Houston health tech startup scores $2.5M SBIR grant to advance unique cell therapy AI technology

fresh funding

A Houston biotech company just announced a new award of $2.5 million.

CellChorus, a spinoff of the Single Cell Lab at the University of Houston, announced the fresh funding, which comes from an SBIR (Small Business Innovation Research) grant from the National Institute of Health (NIH) through its National Center for Advancing Translational Sciences (NCATS).

CellChorus is the business behind a technology called TIMING, which stands for Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visualization AI program that helps scientists to better understand the functioning of cells, including their activation, killing and movement. This more in-depth knowledge of immune cells could be instrumental in developing novel therapies in countless disorders, including cancers and infectious diseases.

“While many cell therapies have been approved and are in development, the industry needs an integrated analytical platform that provides a matrix of functional readouts, including cell phenotype and metabolism on the same cells over time,” Rebecca Berdeaux, vice president of science at CellChorus, says in a press release. “We are grateful to NCATS for its support of the development of application-specific kits that apply dynamic, functional single-cell analysis of immune cell phenotype and function. The product we will develop will increase the impact of these therapies to improve the lives of patients.”

A two-year, $2.1 million Phase II grant will begin after the company achieves predetermined milestones under a $350,000 Phase I grant that is currently taking place. As Berdeaux explained, the funds will be used to develop TIMING kits which will manufacture analytics that provide end-users with rapid, specific and predictive results to accelerate translational research and the development and manufacture of more effective cell therapies.

TIMING is more than a great idea whose time has yet to come. It has already been proven in great depth. In fact, last June, CellChorus CEO Daniel Meyer told InnovationMap that he was initially attracted to the technology because it was “very well validated.” At the time, CellChorus had just announced a $2.3 million SBIR Fast-Track grant from the National Institute of General Medical Sciences. The company also went on to win an award in the Life Science category of the 2023 Houston Innovation Awards.

That confirmation of success comes from more than 200 peer-reviewed papers that describe myriad cell types and types of therapy, all of which used data from TIMING assays. TIMING data has benefited industry leaders in everything from research and clinical development to manufacturing. With the new grant, TIMING will become more widely available to scientists making important discoveries relating to the inner workings of the cells that drive our immunity.

The NIH grant goes toward TransplantAI's work developing more precise models for heart and lung transplantation. Photo via Getty Images

Houston health tech company scores $2.2M grant to use AI to make organ transplants smarter, more successful

future of medicine

The National Institute of Health has bestowed a Houston medtech company with a $2.2 million Fast-Track to Phase 2 award. InformAI will use the money for the product development and commercialization of its AI-enabled organ transplant informatics platform.

Last year, InformAI CEO Jim Havelka told InnovationMap, “A lot of organs are harvested and discarded.”

TransplantAI solves that problem, as well as organ scarcity and inefficiency in allocation of the precious resource.

How does it work? Machine learning and deep learning from a million donor transplants informs the AI, which determines who is the best recipient for each available organ using more than 500 clinical parameters. Organ transplant centers and organ procurement organizations (OPOs) will be able to use the product to make a decision on how to allocate each organ in real time. Ultimately, the tool will service 250 transplant centers and 56 OPOs around the United States.

The NIH grant goes toward developing more precise models for heart and lung transplantation (kidney and liver algorithms are further along in development thanks to a previous award from the National Science Foundation), as well as Phase 2 efforts to fully commercialize TransplantAI.

"There is an urgent need for improved and integrated predictive clinical insights in solid organ transplantation, such as for real-time assessment of waitlist mortality and the likelihood of successful post-transplantation outcomes," according to the grant’s lead clinical investigator, Abbas Rana, associate professor of surgery at Baylor College of Medicine.

“This information is essential for healthcare teams and patients to make informed decisions, particularly in complex cases where expanded criteria allocation decisions are being considered," Rana continues. "Currently, the separation of donor and recipient data into different systems requires clinical teams to conduct manual, parallel reviews for pairing assessments. Our team, along with those at other leading transplant centers nationwide, receives hundreds of organ-recipient match offers weekly.”

Organ transplantation is moving into the future, and Transplant AI is at the forefront.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Booming Houston suburb launches innovation grant to attract startups

innovation incentive

Think you’ve got a burgeoning startup? Consider moving it to southwest Houston. The City of Sugar Land announced the Sugar Land Starts Innovation Fund last week to support companies that move jobs to the area.

“The Sugar Land Starts Innovation Fund is designed to support companies that are ready to grow and make a meaningful, long-term commitment to our community,” Colby Millenbruch, business recruitment manager for the City of Sugar Land, said in a news release. “By focusing on revenue-generating startups and performance-based incentives, we are creating a clear pathway for innovative companies to scale while reenergizing existing office space.”

The performance-based, non-equity dilutive grant program is open to companies that demonstrate at least $250,000 in generated revenue or $500,000 in institutional backing from a bank or venture capital firm. They must commit to hiring or relocating at least three employees in Sugar Land for a minimum of three years and at an average salary of $61,240. Compliance will be verified through Texas Workforce Commission reporting.

The fund builds off the Sugar Land Plug and Play partnership to turn the city into an innovative technology hub.

Collaboration with the Silicon Valley-based startup incubator and accelerator on a physical location in southwest Houston has supported 22 startups and has raised $6.5 million in capital since it officially launched in Sugar Land last March. Companies located at the Sugar Land Plug and Play include Synaps, a browser-based design platform for architects, and Intero Biosystems, which produces miniature human organs for preclinical drug development.

In addition to direct funding and business space, both the new grant and the overall Plug and Play project facilitate meetings with Houston-area businesses like CenterPoint Energy.

This should not only bring new industries to Sugar Land, but also allow existing companies to expand outward as technological investors to create a web of new progress.

“This investment is about more than technology. It’s about creating an environment where innovation can take root, grow, and deliver lasting value for the Sugar Land community,” David Steele, director of Texas at Plug and Play, added in the release. “Sugar Land is setting itself apart by taking a long-term view, investing in founders, partnerships, and technologies that will define the next chapter of growth. We’re proud to partner with the city in building an innovation ecosystem that benefits both entrepreneurs and the broader community.”

Income study shows $100,000 salary goes further in Houston in 2026

Money Talk

A 2026 income study has good news for big earners in Houston: A six-figure salary goes further than it did last year.

A Houston resident's $100,000 salary is worth $84,840 after taxes and adjusted for the local cost of living, according to the new financial analysis from SmartAsset. That's about $1,500 more than Houstonians were bringing home last year.

The 2026 take-home pay is about 8 percent higher than it was in 2024, when the same salary had an adjusted value of $78,089.

SmartAsset used its paycheck calculator to apply federal, state and local taxes to an annual salary of $100,000 in 69 of the largest American cities. The figure was then adjusted for the local cost of living (which included average costs for housing, groceries, utilities, transportation, and miscellaneous goods and services). Cities were then ranked based on where a six-figure salary is worth the least after applicable taxes and cost of living adjustments.

Houston ranked No. 60 in the overall ranking of U.S. cities where $100,000 is worth the least. If the rankings were flipped and the cities were ranked based on where $100,000 goes the furthest, that places Houston in the No. 10 spot nationwide.

Manhattan, New York remains the No. 1 city where a six-figure salary is worth the least. A Manhattan resident's take-home pay is only worth $29,420 after taxes and adjusted for the cost of living, which is 3.10 percent lower than it was in 2025.

SmartAsset determined Manhattan has a 29.7 percent effective tax rate on six-figure salaries. Meanwhile, the effective tax rate on a $100,000 salary in Texas (based on the eight cities examined in the report) is 21.1 percent. It's worth highlighting that New York implements a statewide graduated-rate income tax from 4-10.90 percent, whereas Texas is one of only eight states that don't tax residents' income.

Oklahoma City, No. 69, is the U.S. city in the report where a $100,000 salary stretches the furthest. A six-figure salary is worth $91,868 in 2026, up from $89,989 last year.

This is the post-tax value of a $100,000 salary in other Texas cities, and their ranking in the report:

  • Plano (No. 27): $72,653
  • Dallas (No. 47): $80,103
  • Austin (No. 53): $82,446
  • Lubbock (No. 59): $84,567
  • San Antonio (No. 62): $86,419
  • El Paso (No. 67): $90,276
  • Corpus Christi (No. 68): $91,110
According to the report, getting some "financial breathing room" by making six-figures really depends on where someone lives and what their lifestyle is. For residents living in the 42 states that levy some amount of income tax, their take-home pay dwindles further."And depending on how taxes are filed, reaching a $100,000 income may push a household from the 22 percent to 24 percent marginal tax bracket," the report's author wrote. "Meanwhile, locations with high costs across housing and everyday essentials may be less forgiving to a $100,000 income."

---

This article originally appeared on CultureMap.com.

Rice University partners with astronaut foundation to offer new STEM scholarship

space scholars

Rice University has partnered with The Astronaut Scholarship Foundation (ASF) to offer a new scholarship opportunity for junior or senior STEM majors, beginning this spring.

The prestigious Astronaut Scholarship includes up to $15,000, mentorship, networking and a paid trip to the ASF Innovators Symposium and Gala. The scholarship is funded by the James A. Lovell Jr. Family Endowment, in honor of the late American astronaut and founder of the ASF.

“This scholarship opportunity represents an exciting new avenue for Rice STEM students to synthesize their experiences in courses and research and their commitment to advancing the public good as leaders in their field,” Danika Brown, executive director for the Center for Civic Leadership at Rice, said in a news release. “We are so grateful to the Lovell family and to the foundation for investing in Rice students, and we are confident that the foundation will be impressed with our nominees and that selected students will have a life-changing experience as astronaut scholars.”

The Rice Space Institute and the Center for Civic Learning recently hosted the ASF at the Ralph S. O’Connor Building for Engineering and Science.

At the ASF event, Jeff Lovell—son of James Lovell, who commanded Apollo 13 and flew on Apollo 8—announced the scholarship aimed at Rice STEM students. Charlie Duke, who served as spacecraft communicator for the Apollo 11 Moon landing and as the lunar module pilot for Apollo 16, also spoke at the event.

The ASF awarded 74 scholarships to students from 51 universities across the U.S. last May.

The ASF awarded its first seven $1,000 scholarships in 1986 to pay tribute to the Mercury 7 astronauts. It has since awarded more than $10 million to more than 850 college students.

So far, only students from Texas A&M University and the University of Texas at Austin have received the scholarship in Texas.

View All Listings